Area of research
Oncology · Cancer Research
Research interest
Research interests include HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, and BRCA gene mutations in cancer.
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
A glycolytic metabolite bypasses “two-hit” tumor suppression by BRCA2
FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations
Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Analysis of clinically relevant variants from ancestrally diverse Asian genomes
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Whole-exome sequencing of BRCA-negative breast cancer patients and case–control analyses identify variants associated with breast cancer susceptibility
Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia
Insights Into Breast Cancer in the East vs the West
Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy
Global kinome silencing combined with 3D invasion screening of the tumor microenvironment identifies fibroblast-expressed PIK3Cδ involvement in triple-negative breast cancer progression
Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
Triple negative breast cancer in Asia: An insider’s view
Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment
Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results